| DESCRIPTION | - AARON L. NELSON, MABS, (201001), vol. 2, no. 1, pages 77 - 83 | - |
| DESCRIPTION | - BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 7843 - 7848 | - |
| DESCRIPTION | - CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, page 4285 | - |
| DESCRIPTION | - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, page 901 | - |
| DESCRIPTION | - CRAMER ET AL., CURR. TOP. MICROBOL. IMMUNOL., (1999), vol. 240, pages 95 - 118 | - |
| DESCRIPTION | - EREN ET AL., IMMUNOL, (1998), vol. 93, pages 154 - 161 | - |
| DESCRIPTION | - FISCHER ET AL., BIOTECHNOL. APPL. BIOCHEM., (199910), vol. 30, pages 99 - 108 | - |
| DESCRIPTION | - FISHWALD ET AL., NAT BIOTECHNOL, (1996), vol. 14, no. 7, pages 845 - 851 | - |
| DESCRIPTION | - GOODMAN; GILMAN'S, The Pharmaceutical Basis of Therapeutics, MCGRAW-HILL | - |
| DESCRIPTION | - GRAY ET AL., J. IMM. METH., (1995), vol. 182, pages 155 - 163 | - |
| DESCRIPTION | - GREEN ET AL., NATURE GENETICS, (1994), vol. 7, pages 13 - 21 | - |
| DESCRIPTION | - HAMURO ET AL., J. BIOMOL. TECHNIQUES, (2003), vol. 14, pages 171 - 182 | - |
| DESCRIPTION | - HANES ET AL., PROC. NATL. ACAD. SCI. USA, (199705), vol. 94, pages 4937 - 4942 | - |
| DESCRIPTION | - HANES ET AL., PROC. NATL. ACAD. SCI. USA, (199811), vol. 95, pages 14130 - 14135 | - |
| DESCRIPTION | - HORN ET AL., BIOCHEMISTRY, (2006), vol. 45, pages 8488 - 8498 | - |
| DESCRIPTION | - "In Vitro Immunization in Hybridoma Technology", JONAK ET AL., Progress Biotech, ELSEVIER SCIENCE PUBLISHERS B.V., (1988), vol. 5 | - |
| DESCRIPTION | - JONES ET AL., NATURE, (1986), vol. 321, page 522 | - |
| DESCRIPTION | - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - |
| DESCRIPTION | - KENNY ET AL., BIO/TECHNOL., (1995), vol. 13, pages 787 - 790 | - |
| DESCRIPTION | - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497 | - |
| DESCRIPTION | - LINES ET AL., CANCER RESEARCH, (2014), vol. 74, page 1924 | - |
| DESCRIPTION | - LONBERG ET AL., INT REV IMMUNOL, (1995), vol. 13, no. 1, pages 65 - 93 | - |
| DESCRIPTION | - LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859 | - |
| DESCRIPTION | - MA ET AL., PLANT PHYSIOL., (1995), vol. 109, pages 341 - 6 | - |
| DESCRIPTION | - MA ET AL., TRENDS BIOTECHNOL., (1995), vol. 13, pages 522 - 7 | - |
| DESCRIPTION | - MENDEZ ET AL., NATURE GENETICS, (1997), vol. 15, pages 146 - 156 | - |
| DESCRIPTION | - MILSTEIN; CUELLO, NATURE, (1983), vol. 305, page 537 | - |
| DESCRIPTION | - NGUYEN ET AL., MICROBIOL. IMMUNOL., (1997), vol. 41, pages 901 - 907 | - |
| DESCRIPTION | - POWELL ET AL., BIOTECHNOL., (1990), vol. 8, pages 333 - 337 | - |
| DESCRIPTION | - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623 | - |
| DESCRIPTION | - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY | - |
| DESCRIPTION | - RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323 | - |
| DESCRIPTION | - SANDHU ET AL., CRIT. REV. BIOTECHNOL., (1996), vol. 16, pages 95 - 118 | - |
| DESCRIPTION | - SIMS ET AL., J. IMMUNOL, (1993), vol. 151, page 2296 | - |
| DESCRIPTION | - STEENBAKKERS ET AL., MOLEC. BIOL. REPORTS, (1994), vol. 19, pages 125 - 134 | - |
| DESCRIPTION | - SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210 | - |
| DESCRIPTION | - TAYLOR ET AL., INT. IMMUNOL., (1994), vol. 6, no. 4, pages 579 - 591 | - |
| DESCRIPTION | - TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, (1992), vol. 20, no. 23, pages 6287 - 6295 | - |
| DESCRIPTION | - TRAUNECKER ET AL., EMBO J., (1991), vol. 10, page 3655 | - |
| DESCRIPTION | - TUAILLON ET AL., PROC NATL ACAD SCI USA, (1993), vol. 90, no. 8, pages 3720 - 3724 | - |
| DESCRIPTION | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534 | - |
| DESCRIPTION | - WEN ET AL., J. IMMUNOL, (1987), vol. 17, pages 887 - 892 | - |
| DESCRIPTION | - WHITELAM ET AL., BIOCHEM. SOC. TRANS., (1994), vol. 22, pages 940 - 944 | - |
| DESCRIPTION | - WU, T. T.; KABAT, E. A., JEXP MED, (1970), vol. 132, pages 211 - 50 | - |
| DESCRIPTION | - WANG ET AL., "VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses", J EXP. MED., (2011), vol. 208, no. 3, doi:doi:10.1084/jem.20100619, pages 577 - 92, XP055387118 | |
| DESCRIPTION | - JEFFREY SCHLOM, "Therapeutic Cancer Vaccines: Current Status and Moving Forward", JNATL CANCER INST, (2012), vol. 104, doi:doi:10.1093/jnci/djs033, pages 599 - 613, XP002735513 | |
| EXAMINATION | - GUPTA SHILPA ET AL, "Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.", CANCERS 27 JAN 2017, (20170127), vol. 9, no. 2 | - |
| EXAMINATION | - KONISHI JUN ET AL, "B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 01 AUG 2004, (20040801), vol. 10, no. 15, ISSN 1078-0432, pages 5094 - 5100 | - |
| EXAMINATION | - LAWRENCE MICHAEL S ET AL, "Mutational heterogeneity in cancer and the search for new cancer-associated genes.", NATURE 11 JUL 2013, (20130711), vol. 499, no. 7457, ISSN 1476-4687, pages 214 - 218 | - |
| EXAMINATION | - LE MERCIER ISABELLE ET AL, "VISTA Regulates the Development of Protective Antitumor Immunity.", CANCER RESEARCH 01 APR 2014, (20140401), vol. 74, no. 7, ISSN 1538-7445, pages 1933 - 1944 | - |
| EXAMINATION | - LINES J LOUISE ET AL, "VISTA is an immune checkpoint molecule for human T cells.", CANCER RESEARCH 01 APR 2014, (20140401), vol. 74, no. 7, ISSN 1538-7445, pages 1924 - 1932 | - |
| EXAMINATION | - LINES J LOUISE ET AL, "VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.", CANCER IMMUNOLOGY RESEARCH JUN 2014, (201406), vol. 2, no. 6, ISSN 2326-6074, pages 510 - 517 | - |
| EXAMINATION | - RIZVI NAIYER A ET AL, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.", SCIENCE (NEW YORK, N.Y.) 03 APR 2015, (20150403), vol. 348, no. 6230, ISSN 1095-9203, pages 124 - 128 | - |
| EXAMINATION | - TOPALIAN SUZANNE L ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 28 JUN 2012, (20120628), vol. 366, no. 26, ISSN 1533-4406, pages 2443 - 2454 | - |
| INTERNATIONAL-SEARCH-REPORT | - WOLFF ANTONIO C ET AL, "AMERICAN SOCIETY OF CLINICAL ONCOLOGY/COLLEGE OF AMERICAN PATHOLOGISTS GUIDELINE RECOMMENDATIONS FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 TESTING IN BREAST CANCER", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, COLLEGE OF AMERICAN PATHOLOGISTS, US, (20070101), vol. 131, no. 1, ISSN 0003-9985, pages 18 - 43, XP008077476 [T] 40 * the whole document * | - |
| INTERNATIONAL-SEARCH-REPORT | - LADJEMI MAHA ZOHRA ET AL, "Anti-HER2 vaccines: new prospects for breast cancer therapy.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII SEP 2010, (201009), vol. 59, no. 9, ISSN 1432-0851, pages 1295 - 1312, XP002741123 [A] 71,72 * page 1302 * | |
| INTERNATIONAL-SEARCH-REPORT | - WANG LI ET AL, "VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.", THE JOURNAL OF EXPERIMENTAL MEDICINE 14 MAR 2011, (20110314), vol. 208, no. 3, ISSN 1540-9538, pages 577 - 592, XP002738331 [X] 1-10,12,19-28,31,33-44,46-49,51-58,100-103 * table 10 * [I] 11,50,60,62-66,73-99 | |
| OPPOSITION | - Anonymous, "FITC anti-mouse PD-1H (VISTA) Antibody.", BioLegend, (20110101), pages 1 - 2, XP055781898 | - |
| OPPOSITION | - Anonymous, "ImmuNext Enters into a Strategic Partnership with Janssen, a subsidiary of Johnson and Johnson, to Develop Novel Immunotherapies for the Treatment of Cancer", immunotext, (20120101), pages 1 - 1, immunotext, URL: http://www.immunext.com/latest-news/, (20220922), XP055963878 | - |
| OPPOSITION | - anonymous, "in vivo evaluation of anti vista 13f3 antibody in the ll/2 murine lung tumor model", Experimental results with LL2 N/A model | - |
| OPPOSITION | - Anonymous, "non-small cell lung cancer ", union for international cancer control, (20140101), pages 1 - 18, XP055963887 | - |
| OPPOSITION | - ARENBERG DOUGLAS A ET AL, "Macrophage infiltration in human non-small-cell lung cancer: The role of CC chemokines", Cancer Immunology, Immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg, (20000501), vol. 49, ISSN 0340-7004, pages 63 - 70, XP002506171 | - |
| OPPOSITION | - Bremnes Roy M, Et Al, "The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis Emphasis on Non-small Cell Lung Cancer", Journal of Thoracic Oncology, (20110401), vol. 6, no. 4, pages 824 - 833, XP055781901 | - |
| OPPOSITION | - Li Wang, "VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor T cell responses", Presentation at the SITC 26th Annual Meeting, (20111106), pages 1 - 29, Presentation at the SITC 26th Annual Meeting, (20201016), XP055740845 | - |
| OPPOSITION | - Piascik Michael T, "Receptors Workbook PHA 522/OBI 826", Receptors Workbook PHA 522/OBI 826, (20051011), pages 1 - 8, Receptors Workbook PHA 522/OBI 826, URL: http://www.uky.edu/~mtp/pha522mp/PHA522mp.html, (20210304), XP055781889 | - |
| OPPOSITION | - Rao Arpit, Et Al, "A review of avelumab in locally advanced and metastatic bladder cancer", Therapeutic Advances in Urology, (20190101), pages 1 - 7, Therapeutic Advances in Urology, URL: https://journals.sagepub.com/doi/pdf/10.1177/1756287218823485, (20210304), XP055781990 | - |
| OPPOSITION | - Walser Tonya C, Et Al, "Tumor Microenvironment", Lung Cancer, Humana Press, (20100101), pages 27 - 69, XP055781905 | - |
| OPPOSITION | - WANG et al., "Immune checkpoint protein VISTA regulate autoimmunity and anti-tumor immunity (P2069", THE JOURNAL OF IMMUNOLOGY, (20130501), vol. 190, XP055357336 | - |
| OPPOSITION | - Wells T N.C, Et Al, "new biological therapeutics in the genome age", Biologics in General Medicine, Springer, (20070101), XP055781894 | - |
| OPPOSITION | - WOLFF et al., "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, COLLEGE OF AMERICAN PATHOLOGISTS, (20070101), vol. 131, no. 1, pages 18 - 43, XP008077476 | - |
| OPPOSITION | - Justilien Verline, Fields Alan P., "Utility and Applications of Orthotopic Models of Human Non‐Small Cell Lung Cancer (NSCLC) for the Evaluation of Novel and Emerging Cancer Therapeutics", Current Protocols in Pharmacology, (20131001), vol. 62, no. 1, doi:10.1002/0471141755.ph1427s62, ISSN 1934-8282, XP055781998 | |
| OPPOSITION | - LADJEMI et al., "Anti-HER2 vaccines: new prospects for breast cancer therapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII, (20100900), vol. 59, no. 9, doi:10.1007/s00262-010-0869-2, pages 1295 - 1312, XP002741123 | |
| OPPOSITION | - Trojan Andreas et al, "Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer", LUNG CANCER., ELSEVIER, AMSTERDAM., NL, NL, (20040501), vol. 44, no. 2, doi:10.1016/j.lungcan.2003.11.004, ISSN 0169-5002, pages 143 - 147, XP055781929 | |
| OPPOSITION | - Esendagli, G et al, "Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer", LUNG CANCER., ELSEVIER, AMSTERDAM., NL, NL, (20080101), vol. 59, no. 1, doi:10.1016/j.lungcan.2007.07.022, ISSN 0169-5002, pages 32 - 40, XP022408366 | |
| OPPOSITION | - Barlesi Fabrice et al, "Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20180924), vol. 19, no. 11, doi:10.1016/S1470-2045(18)30673-9, ISSN 1470-2045, pages 1468 - 1479, XP085521847 | |
| OPPOSITION | - LAWRENCE et al., "Mutational heterogeneity in cancer and the search for new cancer-associated genes", NATURE, (20130711), vol. 499, no. 7457, doi:10.1038/nature12213, pages 214 - 218, XP055251629 | |
| OPPOSITION | - Michael S. Lawrence et al, "Mutational heterogeneity in cancer and the search for new cancer-associated genes", Nature, Macmillan Journals Ltd., etc, London, London, vol. 499, no. 7457, doi:10.1038/nature12213, ISSN 0028-0836, pages 214 - 218, XP055251629 | |
| OPPOSITION | - Craig Murdoch, Munitta Muthana, Seth B. Coffelt, Claire E. Lewis, "The role of myeloid cells in the promotion of tumour angiogenesis", Nature Reviews Cancer, Nature Pub. Group, (20080801), vol. 8, no. 8, doi:10.1038/nrc2444, ISSN 1474175X, pages 618 - 631, XP055152260 | |
| OPPOSITION | - K Hiraoka et al, "Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma", British Journal of Cancer, Harcourt Publishers, (20060130), vol. 94, no. 2, doi:10.1038/sj.bjc.6602934, ISSN 00070920, pages 275 - 280, XP055091301 | |
| OPPOSITION | - TOPALIAN et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235 | |
| OPPOSITION | - Feig C, et al, "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.", Proceedings of the National Academy of Sciences, National Academy of Sciences, US, US, (20131210), vol. 110, no. 50, doi:10.1073/pnas.1320318110, ISSN 0027-8424, pages 20212 - 20217, XP002760317 | |
| OPPOSITION | - WANG et al., "VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses", THE JOURNAL OF EXPERIMENTAL MEDICINE, (20110314), vol. 208, no. 3, doi:10.1084/jem.20100619, pages 577 - 592, XP055387118 | |
| OPPOSITION | - Wang L, et al, "VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.", The Journal of Experimental Medicine, Rockefeller University Press, US, US, (20110314), vol. 208, no. 3, doi:10.1084/jem.20100619, ISSN 0022-1007, pages 577 - 592, XP002738331 | |
| OPPOSITION | - WANG et al., "Immune Checkpoint Protein Vista as a Novel Target for Cancer Immunotherapy", 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, (20120000), page 781, XP055673341 | |
| OPPOSITION | - Da Costa Souza Paola, Et Al, "Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma : Immune response in lung carcinoma", Histopathology, Wiley-Blackwell Publishing Ltd., GB, GB, (20121001), vol. 61, no. 4, doi:10.1111/j.1365-2559.2012.04318.x, ISSN 0309-0167, pages 587 - 596, XP055781918 | |
| OPPOSITION | - RIZVI et al., "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", SCIENCE, NEWYORK, N.Y., (20150403), vol. 348, no. 6230, doi:10.1126/science.aaa1348, pages 124 - 128, XP055566207 | |
| OPPOSITION | - Moro Massimo, Et Al, "Patient-Derived Xenografts of Non Small Cell Lung Cancer: Resurgence of an Old Model for Investigation of Modern Concepts of Tailored Therapy and Cancer Stem Cells", Journal of Biomedicine and Biotechnology, (20120101), vol. 2012, doi:10.1155/2012/568567, ISSN 1110-7243, pages 1 - 11, XP055781996 | |
| OPPOSITION | - Sawant Anandi, Et Al, "Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways", Cancer research, American Association for Cancer Research, US, US, (20131115), vol. 73, no. 22, doi:10.1158/0008-5472.CAN-13-0987, ISSN 0008-5472, pages 6609 - 6620, XP055781932 | |
| OPPOSITION | - J. L. Lines et al, "VISTA Is an Immune Checkpoint Molecule for Human T Cells", Cancer research, American Association for Cancer Research, US, US, (20140401), vol. 74, no. 7, doi:10.1158/0008-5472.CAN-13-1504, ISSN 0008-5472, pages 1924 - 1932, XP055438579 | |
| OPPOSITION | - LINES et al., "VISTA is an immune checkpoint molecule for human T cells", CANCER RESEARCH, (20140400), vol. 74, no. 7, doi:10.1158/0008-5472.CAN-13-1504, pages 1924 - 1932, XP055438579 | |
| OPPOSITION | - LE MERCIER et al., "VISTA regulates the development of protective antitumor immunity", CANCER RESEARCH, (20140400), vol. 74, no. 7, doi:10.1158/0008-5472.CAN-13-1506, pages 1933 - 1944, XP002775903 | |
| OPPOSITION | - LE MERCIER I. ET AL, "VISTA regulates the development of protective antitumor immunity.", CANCER RES., (20140101), vol. 74, no. 7, doi:10.1158/0008-5472.CAN-13-1506, pages 1933 - 1944, XP002775903 | |
| OPPOSITION | - KONSHI et al., "B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression", AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATIONFOR CANCER RESEARCH, (20040801), vol. 10, no. 15, doi:10.1158/1078-0432.CCR-04-0428, pages 5094 - 5100, XP055292163 | |
| OPPOSITION | - Arnold James N., Magiera Lukasz, Kraman Matthew, Fearon Douglas T., "Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1", CANCER IMMUNOLOGY RESEARCH, American Association for Cancer Research, US, US, (20140201), vol. 2, no. 2, doi:10.1158/2326-6066.CIR-13-0150, ISSN 2326-6066, pages 121 - 126, XP055782000 | |
| OPPOSITION | - LINES et al., "VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy", CANCER IMMUNOLOGY RESEARCH, (20140600), vol. 2, no. 6, doi:10.1158/2326-6066.CIR-14-0072, pages 510 - 517, XP055203200 | |
| OPPOSITION | - LINES J. L. ET AL., "VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy", CANCER IMMUNOL. RES., (20140601), vol. 2, no. 6, doi:10.1158/2326-6066.CIR-14-0072, pages 510 - 517, XP002775904 | |
| OPPOSITION | - Marlies E Heuvers et al, "Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment", BMC CANCER, BIOMED CENTRAL, LONDON, GB, LONDON, GB, (20121205), vol. 12, no. 1, doi:10.1186/1471-2407-12-580, ISSN 1471-2407, page 580, XP021135369 | |
| OPPOSITION | - Minu K. Srivastava et al, "Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer", PLoS ONE, vol. 7, no. 7, doi:10.1371/journal.pone.0040677, page e40677, XP055279301 | |
| OPPOSITION | - Wojas-Krawczyk Kamila, Kubiatowski Tomasz, "Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research", Frontiers in Oncology, vol. 10, doi:10.3389/fonc.2020.568174, XP055781936 | |
| OPPOSITION | - Gupta Shilpa, Gill David, Poole Austin, Agarwal Neeraj, "Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions", Cancers, (20170101), vol. 9, no. 12, doi:10.3390/cancers9020015, page 15, XP055963876 | |
| OPPOSITION | - FLIES et al., "A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft Versus Host Disease in Mouse Models", J IMMUNOL, (20120800), vol. 187, no. 4, doi:10.4049/jimmunol.1100660, pages 1537 - 1541, XP055140738 | |
| OPPOSITION | - MOLINA et al., "Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship", MAYO CLIN PROC, (20080000), vol. 83, no. 5, doi:10.4065/83.5.584, pages 584 - 594, XP055487675 | |
